ISR Articles

31. What To Prioritize When Selecting A Phase 1 CRO 6/29/2021

    A critical factor when examining service provider selection is the existence of preferred provider agreements. Keeping this in mind, ISR asks respondents to share their selection criteria in a way that demonstrates these agreements’ impacts on the decision-making process.

32. 2021 CRO Leadership Awards – Exceeding Customer Expectations 6/7/2021

    The vetting process for selecting outsourcing partners is time consuming and complex. To support the process, Life Science Leader and Clinical Leader developed the CRO Leadership Awards. Winning CROs are chosen through impartial market research based on feedback from sponsor companies that utilize outsourcing services.

33. Message To CROs: Keep That Pandemic Tool Belt Handy 6/7/2021

    During the last year, despite countless obstacles and dangers, the pharma industry managed to remain steadfast and get to where we are today – hopefully with COVID-19 in the rear-view mirror. Let’s take a closer look at the numbers.

34. How CROs Can Increase Proposal Success Rates Through Win/Loss Studies 6/1/2021

    Whether your organization’s proposal volume already is large or is currently growing, ISR has the tools to develop a custom win/loss study, helping to increase your win rate.

35. Top 5 improvements Needed In Today's EDC Software Systems 2/16/2021

    EDC systems allow a variety of users to input, review, and present the data obtained throughout a clinical trial. In 2020, 130 respondents responsible for outsourcing EDC were asked how they would improve today’s EDC software systems. See the results in the available infographic.

36. How To Improve eCOA/ePRO Software Systems 1/15/2021

    eCOA/ePRO systems are necessary tools to properly capture, review, and present data collected throughout clinical trial. 118 respondents involved in clinical trials expressed their thoughts regarding what improvements needed to be made to eCOA/ePRO software systems. Find out the top improvements they thought were necessary.

     
37. Why Phase II/III Service Providers Lose Bids 11/13/2020

    In Q2, 2020, ISR asked 146 respondents involved in outsourcing Phase II/III services what is the main reason a CRO may lose bids for Phase II/III work. High cost topped the list, capturing 37% of respondents’ votes. Followed by Lack of therapeutic experience (19%) and Lack of understanding of the trial outcomes (12%).

38. Patient Recruitment Challenges In Rare Disease Studies 10/15/2020

    In Q2, 2020, ISR asked 125 respondents involved in patient recruitment and retention activities for rare disease studies about challenges they face while recruiting patients. The data below show the most challenging issue reported by respondents in finding patients for their recent rare disease studies was Multiple sites with access to only a few patients (42%). Followed by Multiple entities pursuing same small pool of patients (19%) and Rigid inclusion/exclusion criteria leading to high screenout rate (15%).

39. Central IRB Outsourcing Practices By Company Size 8/17/2020

    In Q3, 2019, ISR asked outsourcers of Central IRB services about how uniform the use of Central IRBs is within their organization. In terms of company size, respondents from small companies report that their company uses the same Central IRB on All or most of the studies at a higher rate than those from large companies (45% vs 38%). Mid-size companies were similar to large companies, with 37% of respondents reporting their company used the same Central IRB for all studies.

40. Most Important Selection Criteria For Central IRB Services 7/15/2020

    In Q3, 2019, ISR asked 111 respondents responsible for the selection of Central IRB services about the most important attributes when choosing a Central IRB. Not surprisingly, communication and timeliness are highly valued. Clearly communicates expectations for submissions, Defines time-frames for review and reporting, Is fully AAHRPP accredited, Provides excellent customer service, and Offers fast turnaround time are the most important attributes with more than half of respondents considering them moderately or very important when selecting a Central IRB.